Ascendis Pharma A/S (ASND)
| Market Cap | 9.12B |
| Revenue (ttm) | 376.48M |
| Net Income (ttm) | -391.43M |
| Shares Out | 59.84M |
| EPS (ttm) | -6.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,323 |
| Open | 153.65 |
| Previous Close | 154.58 |
| Day's Range | 151.96 - 155.45 |
| 52-Week Range | 111.09 - 161.00 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 197.36 (+29.48%) |
| Earnings Date | Feb 12, 2025 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology ... [Read more]
Financial Performance
In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is $197.36, which is an increase of 29.48% from the latest price.
News
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Ch...
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, Fe...
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenu...
Ascendis Pharma: Danish Blockbuster Hunter
Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential....
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, in...
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference ...
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available...
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily ...
FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biolog...
Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets
ATHENS, Greece and ALMATY, Kazakhstan, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that ...
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President...
Ascendis Pharma Reports Third Quarter 2024 Financial Results
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug ...
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroid...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADS...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary ...
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum...
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
– U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults
Ascendis Pharma Takes A Big Price Cut On Skytrofa
Shares of Ascendis Pharma are under pressure as the company posted a big Q2 revenue miss, driven by a decision to significantly reduce the net price of Skytrofa. Demand for Skytrofa remains strong and...
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.